Roche Holding AG

Equities

ROG

CH0012032048

Pharmaceuticals

Market Closed - Swiss Exchange 11:30:31 2024-05-16 am EDT 5-day change 1st Jan Change
234.8 CHF +3.21% Intraday chart for Roche Holding AG +5.62% -3.97%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Swiss Market Index Rises; Roche Shines on Promising Weight-loss Drug MT
Global markets live: Cisco, EasyJet, Roche, Netflix, Amazon... Our Logo
Dpa-AFX Overview: COMPANIES from 16.05.2024 - 15:15 DP
News Highlights : Top Company News of the Day - Thursday at 9 AM ET DJ
Roche Shares Climb After Weight-Loss Drug Shows Efficacy in Early-Stage Trial -- Update DJ
Roche Gains as Weight-loss Injection Shows Potential in Early-stage Study MT
ROCHE HOLDINGS AG : Receives a Sell rating from JP Morgan ZD
News Highlights : Top Company News of the Day - Thursday at 7 AM ET DJ
ROCHE HOLDINGS AG : Jefferies remains Neutral ZD
Roche shares boosted by good results in obesity treatment CF
Roche Shares Climb After Weight-Loss Drug Shows Efficacy in Early-Stage Trial DJ
Roche shares gain on obesity drug results from early-stage trial RE
Roche Says Investigational Obesity Drug Reduces Weight in Early-stage Study MT
Swiss Equities Advance as Cool US Inflation Data Boosts Sentiment MT
Roche: HPV self-sampling test approved by the FDA CF
Roche Wins US FDA Approval for HPV Self-collection Diagnostic Tool MT
Roche says FDA approves HPV self-test in US RE
Roche Announces FDA Approval of One of the First HPV Self- Collection Solutions in the U.S., Expanding Access and Screening Options to Help Eliminate Cervical Cancer CI
ROCHE HOLDINGS AG : UBS remains Neutral ZD
Wegovy weight loss sustained for four years in trial, Novo Nordisk says RE
Lonza Affirms FY24 Sales Outlook, Raises Mid-term Growth Guidance MT
Xbrane Biopharma, Stada Sign US Licensing Deal for Lucentis Biosimilar MT
Enable Injections, Inc. Announces Collaboration with Roche to Develop and Commercialize Combination of the enFuse Technology with Specific Roche Development Programs CI
ROCHE HOLDINGS AG : UBS reiterates its Neutral rating ZD
Swiss Equities Close in Red Amid Inflation Spotlight MT
Chart Roche Holding AG
More charts
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Calendar
2024-05-22 - Investor Day
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
234.8 CHF
Average target price
279.4 CHF
Spread / Average Target
+18.99%
Consensus
  1. Stock Market
  2. Equities
  3. ROG Stock
  4. News Roche Holding AG
  5. Roche’s Downbeat Q1 Sales Drag Swiss Market Index to Red
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW